Amarin Stock Price, News & Analysis

Amarin Corporation announced that a new post hoc analysis of the REDUCE-IT study indicates that VASCEPA significantly reduces cardiovascular risks in patients with a history of percutaneous coronary intervention (PCI). The analysis showed a 34% reduction in major cardiovascular events, with absolute risk reductions of 8.5% and 5.4% for primary and secondary endpoints. In total, 3,408 patients were involved, where 37.6% on standard care had major events compared to 25.6% treated with VASCEPA. The findings support VASCEPA's role in reducing recurrent cardiovascular events in high-risk patients.

Amarin Corporation plc (NASDAQ:AMRN) reported a 2021 net revenue of $583.2 million, down 5% from 2020. The net product revenue was $580.3 million, impacted by generic competition and COVID-19 effects. In the U.S., the Go-To-Market strategy is progressing well, with expanded reach to 150,000 healthcare providers. Meanwhile, VAZKEPA has received approval in Europe, and Amarin is advancing regulatory filings in multiple countries. The company remains committed to enhancing cardiovascular outcomes and managing operational costs effectively. A conference call is scheduled for today at 8:00 a.m. ET.

Amarin Corporation (NASDAQ: AMRN) announced that CEO Karim Mikhail will participate in a virtual fireside chat at the Cowen 42nd Annual Health Care Conference on March 7, 2022, from 9:10 AM to 9:40 AM ET. Interested parties can access the live webcast on the company’s investor relations website, which will be archived for 30 days. Amarin focuses on innovative cardiovascular disease management and clinical trials, with a commitment to advancing treatment options.

MedStar Health Research Institute's analysis indicates that icosapent ethyl is cost-effective compared to standard care for high-risk patients with hypertriglyceridemia, both during the REDUCE-IT® clinical trial and in lifetime projections. The evaluation, published in JAMA Network Open, involved over 8,000 patients and demonstrated that icosapent ethyl led to more quality-adjusted life years (QALYs) than standard treatment. The study utilized detailed patient-level data, enhancing the rigor of its cost-effectiveness analysis.

Amarin Corporation plc (NASDAQ: AMRN) announced a conference call with senior management to discuss its fourth quarter and full year 2021 financial results on March 1, 2022, at 8:00 a.m. ET. This call will follow the release of the financial results earlier that day. Investors can access the call through the company’s investor relations website or by dialing in. Amarin focuses on cardiovascular disease management and aims to advance treatment beyond traditional therapies. The replay will be available for two weeks post-call.

Cyteir Therapeutics has appointed John F. Thero to its board of directors, expanding the board from eight to nine members. Thero, who brings over 30 years of experience in financial and operations roles, will chair the audit committee. He is recognized for leading Amarin through critical phases, including the launch of VASCEPA, and has received accolades such as Ernst & Young's Entrepreneur of the Year for Life Sciences. Thero expressed enthusiasm about contributing to Cyteir's growth, targeting advancements in their candidate CYT-0851 for oncology patients.

Amarin Corporation plc (NASDAQ:AMRN) reported preliminary unaudited revenue for 2021 of approximately $580 million, with Q4 revenue around $140 million, stabilizing a previous 8% decline. The company ended 2021 with $490 million in cash and no debt. Amarin's VAZKEPA was approved in Europe, and a fixed dose combination product with a statin is in development. Despite challenges from COVID-19 and generic competition, Amarin's U.S. net revenue is expected to be $575 million. The company is optimistic about future growth prospects in Europe and international markets, but is unable to provide 2022 revenue guidance due to uncertainties.

Amarin Corporation (NASDAQ: AMRN) announced that CEO Karim Mikhail will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 8:15 AM ET. The presentation will be available via a live webcast on the company's investor relations website, where it will also be archived for 30 days. Amarin is dedicated to transforming cardiovascular disease management through innovative research and clinical trials, with a commitment to advancing treatments beyond traditional therapies.

Amarin Corporation has presented new data on VASCEPA/VAZKEPA at the AHA Scientific Sessions 2021. The studies highlighted show that icosapent ethyl reduced total ischemic events by 32% in patients with prior peripheral artery disease (PAD). While safety profiles were generally consistent, there was an increased incidence of atrial fibrillation. Additionally, the PREPARE-IT 2 study did not meet its primary endpoint in evaluating efficacy for COVID-19 hospitalizations. Overall, these findings reinforce the cardiovascular benefits of VASCEPA while opening avenues for further research.